Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Journal of the National Comprehensive Cancer Network : JNCCN|April 4, 2023
Rates of Menstrual History-Taking and Counseling With Anticancer Treatments Are Low: People Who Menstruate Deserve Gender-Specific Cancer CareVerity Chadwick, Michaela Kim, Georgia Mills, et al.
Expert Review of Hematology|October 13, 2025
Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma AustraliaAngelina Yong, Kate Vandyke, Bradley Augustson, et al.
Blood Cancer Journal|March 23, 2024
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysisFieke W Hoff, Rahul Banerjee, Adeel M Khan, et al.
Internal Medicine Journal|August 5, 2025
Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma AustraliaGeorgia McCaughan, Hayley Beer, Christian Bryant, et al.
Pharmacoeconomics|October 29, 2025
A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry DataAdam Irving, Dennis Petrie, Anthony Harris, et al.
Plos One|August 27, 2024
Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registryAdam Irving, Dennis Petrie, Anthony Harris, et al.
Internal Medicine Journal|January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory GroupShirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.
Asia-Pacific Journal of Clinical Oncology|March 23, 2026
Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant-Ineligible Newly Diagnosed Myeloma: An Australian Real-World, Multicenter StudySamantha Kurniawan, Angela Hwang, Nicole Wong Doo, et al.
Blood Advances|July 12, 2022
Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplantWei Jiang, Leighton E Clancy, Selmir Avdic, et al.
Internal Medicine Journal|May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statementGeorgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.
Pageof 3